Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Summary

This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.

Timeline

Start

2003-11

Primary completion

2009-05

Completion

2017-04

Publications

• Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.

Drugs

Indications